LivaNova/$LIVN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LivaNova
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
- Ticker
- $LIVN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,300
- Headquarters
- Gloucester, United Kingdom
- Website
- www.livanova.com
LivaNova Metrics
BasicAdvanced
$5B
26.11
$3.50
0.92
-
Price and volume
Market cap
$5B
Beta
0.92
52-week high
$99.38
52-week low
$52.37
Average daily volume
708K
Financial strength
Current ratio
1.463
Quick ratio
1.081
Long term debt to equity
0.251
Total debt to equity
0.26
Interest coverage (TTM)
6.96%
Profitability
EBITDA (TTM)
275.746
Gross margin (TTM)
67.64%
Net profit margin (TTM)
13.01%
Operating margin (TTM)
14.30%
Effective tax rate (TTM)
-64.33%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
5.11%
Return on equity (TTM)
15.50%
Valuation
Price to earnings (TTM)
26.112
Price to revenue (TTM)
3.323
Price to book
3.67
Price to tangible book (TTM)
13.15
Price to free cash flow (TTM)
38.816
Free cash flow yield (TTM)
2.58%
Free cash flow per share (TTM)
2.353
Growth
Revenue change (TTM)
11.71%
Earnings per share change (TTM)
-187.62%
3-year revenue growth (CAGR)
10.45%
3-year earnings per share growth (CAGR)
312.26%
What the Analysts think about LivaNova
Analyst ratings (Buy, Hold, Sell) for LivaNova stock.
Analyst projections of the future price of LivaNova stock.
Bulls say / Bears say
Third-quarter revenue grew 10% year on year, and LivaNova raised its 2026 revenue-growth and adjusted EPS forecasts. Growth in both major segments gives the upgraded outlook support. (LivaNova PLC)
Strong oxygenator demand is an opportunity, and the company has started production on a dedicated new line to expand supply. Essenz placements and upgrades also offer room to grow as the system remains a minority of its installed base. (LivaNova PLC, Investing.com)
LivaNova’s FDA-approved aura6000 sleep-apnoea device opens a new market opportunity, while new Category I procedure codes are expected to take effect in 2028. That could support patient access, although meaningful commercial growth is still ahead. (LivaNova PLC, LivaNova PLC)
The 3T heater-cooler litigation remains costly and uncertain: LivaNova recorded a further $34 million provision in the third quarter, taking the provision to $44.2 million, and said actual losses may differ from its estimate. (StockTitan)
The separate SNIA environmental case leaves a large liability overhang. LivaNova reported a roughly $385 million current liability in its June filing, while the appeal and potential settlement process remained unresolved. (SEC)
Cash generation is not accelerating as quickly as earnings: third-quarter adjusted free cash flow fell to $55.8 million from $62 million, while capital spending rose to $77 million for the first nine months from $49 million. Capacity expansion and other investment could continue to weigh on near-term cash flow. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
LivaNova Financial Performance
Revenues and expenses
LivaNova Earnings Performance
Company profitability
Upcoming events
No upcoming events
LivaNova News
AllArticlesVideos

LivaNova Q3 Earnings Call Highlights
MarketBeat2 weeks ago

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Business Wire2 weeks ago

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
Business Wire3 weeks ago
Funds containing LivaNova
Fund name | Fund size | $LIVN weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.50% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.50% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.50% |
iShares Ageing Population$AGED | $887M | 0.44% |
iShares Ageing Population£AGES | $887M | 0.44% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.